Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models-Reference-Cited by-同舟云学术

Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models

Published:2023-03 Issue: Volume:189 Page:106692
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Xu Pengfei,Yang Joy C.,Ning Shu,Chen Bo,Nip Christopher,Wei Qiang,Liu Liangren,Johnson Oleta T.,Gao Allen C.,Gestwicki Jason E.,Evans Christopher P.,Liu Chengfei

Funder

National Institutes of Health

DOD

National Cancer Institute

Comprehensive Cancer Center, University of California, Davis

Publisher

Elsevier BV

Subject

Pharmacology

Reference55 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3;Scher;J. Clin. Oncol.,2016